| Ciro Alberto Rincon-prieto, MD | |
|
255 Baptist Blvd Ste 402, Columbus, MS 39705-2006 | |
| (662) 244-2550 | |
| (662) 244-2553 |
| Full Name | Ciro Alberto Rincon-prieto |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 16 Years |
| Location | 255 Baptist Blvd Ste 402, Columbus, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396097788 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 25630 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mississippi Homecare Of Eupora | Eupora, MS | Home health agency |
| Baptist Memorial Hospital Golden Triangle Inc | Columbus, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Memorial Medical Group, Inc. | 5193610228 | 433 |
News Archive
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
Cannabis-based medicines should only be used under medical supervision until clinical studies have assessed their safety and efficacy, a University of Queensland drug expert has cautioned.
As many as 3 percent of all pregnancies result in the birth of a baby with chromosomal anomalies like Down syndrome or structural anomalies such as congenital heart disease.
Women taking 1,000 mg of docosohexanoic acid (DHA) daily in the last half of pregnancy had a lower rate of early preterm birth than women who took the standard 200 mg dose, according to a study funded by the National Institutes of Health.
› Verified 1 days ago
| Entity Name | Baptist Memorial Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306089206 PECOS PAC ID: 5193610228 Enrollment ID: O20101011000028 |
News Archive
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
Cannabis-based medicines should only be used under medical supervision until clinical studies have assessed their safety and efficacy, a University of Queensland drug expert has cautioned.
As many as 3 percent of all pregnancies result in the birth of a baby with chromosomal anomalies like Down syndrome or structural anomalies such as congenital heart disease.
Women taking 1,000 mg of docosohexanoic acid (DHA) daily in the last half of pregnancy had a lower rate of early preterm birth than women who took the standard 200 mg dose, according to a study funded by the National Institutes of Health.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ciro Alberto Rincon-prieto, MD 965 Ridge Lake Blvd Ste 103, Memphis, TN 38120-9446 Ph: (901) 227-3255 | Ciro Alberto Rincon-prieto, MD 255 Baptist Blvd Ste 402, Columbus, MS 39705-2006 Ph: (662) 244-2550 |
News Archive
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
Cannabis-based medicines should only be used under medical supervision until clinical studies have assessed their safety and efficacy, a University of Queensland drug expert has cautioned.
As many as 3 percent of all pregnancies result in the birth of a baby with chromosomal anomalies like Down syndrome or structural anomalies such as congenital heart disease.
Women taking 1,000 mg of docosohexanoic acid (DHA) daily in the last half of pregnancy had a lower rate of early preterm birth than women who took the standard 200 mg dose, according to a study funded by the National Institutes of Health.
› Verified 1 days ago
Fakhri Dalati, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2520 5th St N, Columbus, MS 39705 Phone: 662-244-2042 Fax: 662-244-2041 | |
Dr. Connie Harris Scurti, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd Ste 301, Columbus, MS 39705 Phone: 662-244-1705 Fax: 662-227-4301 | |
Dr. Michael R Duckworth, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2225 5th St N, Columbus, MS 39705 Phone: 662-327-0197 Fax: 662-327-5660 | |
Michael J Boland, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd, Suite 402, Columbus, MS 39705 Phone: 662-240-1412 Fax: 662-240-1949 | |
Dr. Madhukar Saran, M.D Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 824 Alabama St, Columbus, MS 39702 Phone: 662-244-0391 Fax: 662-244-0395 | |
Dr. Paul J Scurti, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd Ste 301, Columbus, MS 39705 Phone: 662-244-1705 Fax: 662-227-4301 | |
Wail Alnas, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 345 Baptist Blvd, Columbus, MS 39705 Phone: 662-244-2288 Fax: 662-244-2763 |